



SEMPERIT GROUP FY 2019 INVESTOR PRESENTATION

Dr Martin Füllenbach, CEO

Petra Preining, CFO

20 March 2020



Corona Update - Health and Safety is Key Priority

People

- Currently no Semperit employees are critically ill with Corona (CoViD-19)
- Prevention is KEY – physical contact reduced to the minimum

Procurement

- Currently no shortage of critical raw materials
- Alternative suppliers available
- Longer delivery times due to long queues at borders in Europe

Production

- For the time being no restrictions of production
- Expected slowdown as illness level and longer delivery periods will increase
- China: after close down for less than two weeks, situation starts to normalise again
- Malaysia: Production at risk due to restrictive measures of the government

Customers

- As of today no decline in the orderbooks attributable to Corona
- Adverse effects in Q2 to expect, however difficult to quantify impact at this stage
- Slowdown of the business is anticipated



Agenda

Highlights 2019 and Restructuring & Transformation update (p.3)

Operational highlights (p.7)

Financial performance (p.14)

Management agenda (p.24)

Appendix (p.27)



Highlights 2019: Adjusted EBITDA +26.8%, reported +46.1%



- Revenue down by 4.3% to € 840.6m
- Decline mainly due to economic slowdown in H2 2019



- Significant improvement both at operating EBITDA and EBIT, despite negative impact of economic cycle
 - Material contribution of transformation and restructuring process
 - Substantial increase of profitability
 - Since 2017 adjusted EBITDA margin almost doubled (from 4.1% to 7.6%)



- Reported EBITDA € 67.8m, **adjusted EBITDA € 63.8m, +26.8% vs. 2018**
- Reported EBIT € –16.5m, **adjusted EBIT € 28.2m vs. € 15.4m in 2018**
- **Net loss almost halved to € 44.9m vs. € 80.4m in 2018**
 - Mostly due to Impairment (€ 48.8m)



- **Free Cash flow generation positive** – after previous periods of cash outflow: **2019 € +60.8m** vs. € –66.8m in 2018
- **Capex at € 31.9 m in 2019** (€ 80.8m in 2018), **lower level to remain below € 40m in 2020**



- **Focus point: new strategic direction**
 - Separation from the medical segment
 - Ongoing continuous focus on profitability, process optimisation, quality improvement and reduction of complexity

- **Focus point: Industry**
 - New industrial rubber strategy with focus on regional and application-related customer intimacy
 - Semperform split into two (Semperform and Semperseal) to enhance focus on new markets



Financial Analysis of Restructuring Impact in 2017-2019

	2017	2018	△	2019	△
Sales	874.2	878.5	0.5% ↗	840.6	-4.3% ↘
Adj. EBITDA	35.8	50.3	40.6% ↗	63.8	26.8% ↗
Adj EBITDA margin	4.1%	5,7%	1.6 PP ↗	7.6%	1.9 PP ↗
Adj EBIT	-0.8	15.4	(-) ↗	28.2	83.4% ↗
Adj EBIT margin	-0.1%	1.7%	1.8 PP ↗	3.4%	1.7 PP ↗
Adj net profit	-43.3	-17.3	-60.% ↗	-0.2	-98.9% ↗


- > 570 measures implemented by 31 December 2019 out of ~800 measures identified
- Sales impacted by operational streamlining and economic slowdown in H2'2019
 - Closure of Sempertrans locations in France and China
 - Sale of Semperflex location in Italy
 - Semperform: service functions for Dalheim centralized in Hückelhoven
- Further upside to come from operational and growth initiatives as part of SemperGrowth200
- Improved results and working capital management together with a reduced CAPEX level result in positive free cashflow

Adjusted figures for operational performance



Transformation programme with tangible material impact and operational performance significantly up at EBITDA/EBIT level

→ On the back of successful transformation programme, significant improvements



- **Revenue –4.3%** for Group
 - –3.5% for Industrial Sector
 - –5.8% for Medical Sector
- **Adjusted EBITDA +26.8%** for Group
 - +16.3% for Industrial Sector to € 87.5m, restructuring measures in all segments contributed to profitability uplift
 - Medical Sector positive again at € 1.4m on adjusted level
- **Positive adjusted EBIT** of € 28.2m vs. EBIT of € 15.4m in 2018



Agenda

Highlights 2019 and Restructuring & Transformation update (p.3)

Operational highlights (p.7)

Financial performance (p.14)


Management agenda (p.24)

Appendix (p.27)



Revenue development

in € m





Revenue development

- **Semperflex:** Reduced market demand due to destocking
- **Sempertrans:** Lower volumes as a result of focus shift to quality of order book and product profitability
- **Semperform:** Almost stable despite reduced market demand
- **Sempermed:** Lower sales due to strategic change in production portfolio (focus on Nitrile) and reduced outsourcing, thus less traded goods

¹⁾ Change of each segment / sector for FY 2019 vs FY 2018.




Industrial Sector adjusted EBITDA 2019 and Q4 2019



¹⁾2018 and Q2'18 EBITDA adjusted by € 4m due to closure of Sempertrans site in China.




Semperflex 2019



Semperflex



2019 vs. 2018



- Revenue slightly down due to reduced market demand as a result of destocking combined with more cautious stock management
- EBITDA in 2019 slightly below 2018 yoy, while EBITDA margin nearly unchanged
- Size of order book decreased significantly compared to 2018 – competitive pressure expected to increase further
- Ongoing destocking and lower demand of customer base expected to have a negative impact on sales and EBITDA in the coming quarters







Sempertrans 2019

2018 vs 2019: >100% EBITDA yoy, € +9.1m

Sempertrans



2019 vs. 2018



- Successful turnaround after closure of Sempertrans sites (FRA & CHN), improved operational performance and quality of order book
- Significant increase in EBITDA yoy²⁾
- Strong improvement of EBITDA margin from 3.0% in 2018 to 10.1% in 2019
- Order book slightly under pressure due to reduced market demand especially in European lignite industry



¹⁾ 2018 EBITDA: adjusted by € 4m due to closure of Sempertrans site in China.

²⁾ 2019 EBITDA: positive effects of € 1.3m profit from sale of assets of closed factory in China, and + € 1.7 m insurance claim.




Semperform 2019

2018 vs 2019: +18.8% EBITDA yoy, € +4.1m

Semperform



2019 vs. 2018



- Revenue stable despite reduced market demand
- Further EBITDA (+18.8%) and EBITDA margin (+2.2PP) improvement
- Economic downturn impacts order book
- As of 1 Jan 2020 split of the Segment into
 - Semperform (handrail, liners, foils, Engineered Solutions)
 - Sempersal (profiles, sheeting)






Medical Sector / Sempermed segment 2019

Medical Sector

Sempermed



2019 vs. 2018

Revenue current period

293

Revenue comparable period

312

EBITDA¹⁾ current period

1

EBITDA comparable period

-4

in € m

- Significant operational improvements resulted in higher profitability
- Lower revenue level mainly driven by strategic change in production portfolio (focus on Nitrile) and reduced outsourcing
- Order book declined in H2'19 mainly due to inventory streamlining by key business customers and increasingly difficult market conditions
- Impairment of 48.8m EUR booked to reflect increase in competition and related CAPEX requirements



¹⁾ 2019 and Q3'19 EBITDA adjusted for € 4m due to release of provision in Sempermed for Brazilian court case for tax liabilities



Agenda

Highlights 2019 and Restructuring & Transformation update (p.3)

Operational highlights (p.7)

Financial performance (p.14)

Management agenda (p.24)

Appendix (p.27)



Financials and Profitability Overview

in € m	FY 2019	FY 2018	Change	Change in EUR m
Revenue	840.6	878.5	-4.3%	-37.9
EBITDA adjusted¹⁾	63.8	50.3	+26.8%	+13.5
EBITDA margin adjusted	7.6%	5.7%	+1.9 PP	–
EBITDA	67.8	46.4	+46.1%	+21.4
EBITDA margin	8.1%	5.3%	+2.8 PP	–
EBIT adjusted¹⁾	28.2	15.4	+83.4%	+12.9
EBIT margin adjusted	3.4%	1.7%	+1.7 PP	–
EBIT	-16.5	-47.7	-65.4%	+31.2
EBIT margin	-2.0%	-5.4%	+3.4 PP	–
Earnings after tax adjusted¹⁾	-0.2	-17.3	-98.9%	+17.1
Earnings after tax	-44.9	-80.4	-44.1%	+35.4
Earnings per share (EPS) adj.²⁾, in EUR	-0.33	-1.07	-69.0%	+0.7
Earnings per share (EPS)²⁾, in EUR	-2.50	-4.13	-39.5%	+1.6


- 1) FY 2018 adjusted for negative one-off effect of € 55m from impairment of Sempermed (adj. for EBIT and EAT only) and for closure of Sempertrans site in China of € 4m (EBITDA) / € 8m (EBIT, EAT).
FY 2019 adjusted for positive one-off effects of € 4m (EBITDA, EBIT, EAT) due to release of provision in Sempermed for Brazilian court case for tax liabilities and for negative one-off effects of € 48.8m from impairment at Sempermed from impairment of Sempermed (adj. for EBIT and EAT)

- 2) Attributable to the shareholders of Semperit AG Holding from ordinary shares, excluding interest from hybrid capital.



Revenue development


in € m



¹⁾ Change of each segment / sector for FY 2019 vs FY 2018.



From reported to adjusted EBITDA / EBIT 2019



- EBITDA: following the positive decision on November 12th 2019 of the Brazilian courts with regards to tax liabilities, the amount of EUR 4.0 m were released from provisions (effective in the segment Sempermed, recognised as a one-off item) – reported figures are adjusted accordingly
- EBIT: Impairment losses at EUR 48.8 m were recognised in the segment Sempermed due to the significant increase of the competitive environment – thus reported EBIT amounts to EUR -16.5m, while adjusted EBIT reaches EUR 28.2m


1) 2019 EBITDA: Sempertrans includes positive effects of € 1.3m profit from sale of assets of closed factory in China and € 1.9 m insurance claim; reported figures not adjusted

2) 2019 EBIT: Sempermed impairment adjusted for year end closing due to FX changes and additions, thus changed from € 46.8m at the end of Q3'19 to € 48.8m



Adjusted EBITDA development

in € m



	FY 2018	Semperflex	Sempertrans	Semperform	Sempermed	Corporate	FY 2019
Operating EBITDA FY 2018 ¹⁾	50.3m	48.9m	4.4m	21.9m	-3.9m	-21.0m	
Operating EBITDA FY 2019 ²⁾		47.9m	13.5m	26.0m	1.4m	-25.1m	63.8m
Operating EBITDA margin FY 2019		21.5%	10.1%	13.6%	0.5%	–	7.6%



Change of intercompany consolidation included in Corporate

1) FY 2018 adjusted for negative one-off effects of € 4m from closure of Sempertrans production site in China.

2) FY 2019 adjusted for positive one-off effects of € 4m due to release of provision in Sempermed for Brazilian court case for tax liabilities.



Sempermove10 shows material impact: Consistent yoy EBITDA improvement for 8th consecutive quarter



- Profitability improvement clearly visible
- EBITDA 2019 by 27% above 2018 and Q4'19 even by 64% above Q4'18

¹⁾ 2018 and Q2 2018 EBITDA adjusted by € 4m due to closure of Sempertrans site in China.

²⁾ 2019 and Q3 2019 EBITDA adjusted by € 4m due to release of provision in Sempermed for Brazilian court case for tax liabilities.




CAPEX by quarter

- FY 2018: overall CAPEX of € 81m, approx. 50% for Semperflex and mixing
- FY 2019: overall CAPEX of € 32m - predominantly maintenance

CAPEX per segment

in € m






Working Capital Overview

Components of Working Capital

in € m




¹⁾ Trade Working Capital in % of LTM revenues



Free cash flow development

- Improved results, active WC management and strict CAPEX control support cashflow development
- First positive free cash flow after being negative in the previous years

Development of cash flow components¹⁾
in € m



¹⁾ Cash flow calculation methodology change as of end of 2018, numbers for 2016 and 2017 adjusted accordingly: “interest received” is now shown under cash flow from investing activities instead of operating activities, “interest paid” now included in cash flow from financing activities instead of operating activities.


²⁾ 2017 investment cash flow adjusted by 160 EUR m (Joint Venture Termination)



Balance sheet structure and financial profile

Balance sheet structure

Balance sheet 31/12/2019: € 702m
Balance sheet 31/12/2018: € 769m



Financial profile as of 31 December 2019

- Cash and cash equivalents of € 141m
- Financial liabilities:
 - Corporate Schuldschein loan partially already re-paid, thus at € 209m
 - Liabilities to banks of € 6m
- Net debt of € 73.5m
 - down by € 39.2m since end of Dec. 2018
 - Net debt / EBITDA of 1.1x, compared to 2.4x as of end of Dec. 2018
- Hybrid capital of € 130m strengthens equity remaining undrawn € 20m line prolonged until end of 2020
- Equity ratio of 39.0% vs. 42.9% Dec. 2018
- Due to the negative net result no dividend payment in 2020 for 2019



Agenda

Highlights 2019 and Restructuring & Transformation update (p.3)

Operational highlights (p.7)

Financial performance (p.14)

Management agenda (p.24)

Appendix (p.27)



Management agenda 2020



- **Crisis management and taking necessary actions regarding the corona virus**
- Address global economic downturn and take proactive initiatives
- Continue to implement SemperMove10 restructuring and transformation programme for profitability
- Outlook 2020: Significant Topline and Margin Pressure to expect
- Implement new strategy – next steps:
 - Successful execution of the separation from Medical Business
 - Regional diversification with stronger focus on North America
 - Focus on customer intimacy
 - Innovation & digitisation – exploit new growth potentials



Contact and financial calendar

Investor Relations Semperit

Judit Helenyi, Director Investor Relations

+43 1 79777 - 310

www.semperitgroup.com/en/ir

Modecenterstrasse 22

1031 Vienna, Austria

Financial Calendar 2020

20.03.2020	Publication of 2019 annual financial statements
20.05.2020	Report on Q1 2020
22.07.2020	Annual general meeting, Vienna
28.07.2020	Dividend payment day ¹⁾
14.08.2020	Half-year financial report 2020
19.11.2020	Report on Q1-3 2020

¹⁾ No dividend proposed for FY 2019

Disclaimer

The information provided in this presentation does not constitute an offer for the sale of securities nor an invitation to submit an offer to purchase shares of Semperit AG Holding, but exclusively serves information purposes.

The terms “Semperit” or “Semperit Group” in this presentation refer to the group; “Semperit AG Holding” or “Semperit Aktiengesellschaft Holding” is used to refer to the parent company (individual company).

We have prepared this presentation and verified the information it contains with the greatest possible care. Nevertheless, rounding, typesetting and printing errors cannot be ruled out. Rounding of differences in the summation rounded amounts and percentages may arise from the automatic processing of data.

The forecasts, plans and forward-looking statements contained in this presentation are based on the knowledge and information available and the assessments made at the time that this presentation was prepared. As is true of all forward-looking statements, these statements are subject to risk and uncertainties. As a result, actual events may deviate significantly from these expectations. No liability whatsoever is assumed for the accuracy of projections or for the achievement of planned targets or for any other forward-looking statements. Words such as “expect,” “want”, “believe,” “anticipate,” “includes,” “plan,” “assumes,” “estimate,” “projects,” “intends,” “should,” “will,” “shall,” or variations of such words are generally part of forward-looking statements.

Furthermore, there is no guarantee that the contents are complete. Statements referring to people are valid for both men and women.



Agenda

Highlights 2019 and Restructuring & Transformation update (p.3)

Operational highlights (p.7)

Financial performance (p.14)

Management agenda (p.24)

Appendix (p.27)



Sectors and Group: FY 2019 vs FY 2018

in EUR m	Industrial Sector			Medical Sector			Semperit Group ¹⁾		
	FY 2019	FY 2018	%	FY 2019	FY 2018	%	FY 2019	FY 2018	%
Revenue	547.2	567.0	-3.5%	293.3	311.5	-5.8%	840.6	878.5	-4.3%
EBITDA	87.5	71.3	+22.6%	5.5	-3.9	–	67.8	46.4	+46.1%
EBITDA margin	16.0%	12.6%	+3.4 PP	1.9%	-1.3%	+3.2 PP	8.1%	5.3%	+2.8 PP
Adj. EBITDA²⁾	87.5	75.2	+16.3%	1.4	-3.9	–	63.8	50.3	+26.8%
Adj. EBITDA margin ²⁾	16.0%	13.3%	+2.7 PP	0.5%	-1.3%	+1.8 PP	7.6%	5.7%	+1.9 PP
EBIT	60.9	44.6	+36.5%	-50.2	-69.6	-27.9%	-16.5	-47.7	-65.4%
EBIT margin	11.1%	7.9%	+3.2 PP	-17.1%	-22.3%	+5.2 PP	-2.0%	-5.4%	+3.4 PP
Adj. EBIT²⁾	60.9	52.4	+16.2%	-5.5	-14.3	-61.9%	28.2	15.4	+83.4%
Adj. EBIT margin ²⁾	11.1%	9.2%	+1.9 PP	-1.9%	-4.6%	+2.7 PP	3.4%	1.7%	+1.7 PP
Earnings after tax	–	–	–	–	–	–	-44.9	-80.4	-44.1%
Adj. Earnings after tax²⁾	–	–	–	–	–	–	-0.2	-17.3	-98.9%
Earnings per share in EUR	–	–	–	–	–	–	-2.50	-4.13	-39.5%
Adj. Earnings per share in EUR	–	–	–	–	–	–	-0.33	-1.07	-69.0%
Investments	22.7	67.0	-66.4%	8.0	12.7	-35.2%	31.4	80.8	-61.3%
Employees	3,602	3,654	-1.4%	3,165	2,979	+6.2%	6,902	6,773	+1.9%

1) Including Corporate Center costs (Holding, supporting functions, special projects) and consolidation, reported figures: EBITDA: € -25.1m in FY 2019 (€ -21.0m in FY 2018), EBIT € -27.2m in FY 2019 (€ -22.7m in FY 2018).

2) FY 2018 adjusted for negative one-off effect of € 55m from impairment of Sempermed (adj. for EBIT and EAT only), € 4m (EBITDA) / € 8m (EBIT, EAT) from closure of Sempertrans site in China.

FY 2019 adjusted for positive one-off effects of € 4m (EBITDA, EBIT, EAT) due to release of provision in Sempermed for Brazilian court case for tax liabilities and for negative one-off effects of € 48.8m from impairment at Sempermed from impairment of Sempermed (adj. for EBIT and EAT)


3) Attributable to the shareholders of Semperit AG Holding from ordinary shares, excluding interest from hybrid capital.




Semperit Group adj. where applicable

Semperit Group adj. where applicable																
in EUR m	FY 2016 adj. ¹⁾	Q1 2017 adj. ²⁾	Q2 2017 adj. ²⁾	Q3 2017 adj. ²⁾	Q4 2017 adj. ²⁾	FY 2017 adj. ²⁾	Q1 2018	Q2 2018 adj. ³⁾	Q3 2018	Q4 2018	FY 2018	Q1 2019	Q2 2019	Q3 2019 adj. ⁴⁾	Q4 2019	FY 2019
Revenue	852.4	229.3	232.3	208.4	204.2	874.2	220.9	227.6	221.7	208.2	878.5	212.9	224.4	214.9	188.3	840.6
EBITDA	74.7	9.6	12.9	10.4	2.9	35.8	15.8	17.0	13.1	4.5	50.3	16.5	22.7	17.3	7.4	63.8
EBITDA margin	8.8%	4.2%	5.6%	5.0%	1.4%	4.1%	7.1%	7.5%	5.9%	2.2%	5.7%	7.7%	10.1%	8.0%	3.9%	7.6%
EBIT	41.1	1.6	4.6	1.7	-8.7	-0.8	6.0	7.2	4.3	-2.2	15.4	7.8	13.1	8.1	-0.8	28.2
EBIT margin	4.8%	0.7%	2.0%	0.8%	-4.3%	-0.1%	2.7%	3.2%	1.9%	-1.0%	1.7%	3.7%	5.8%	3.8%	-0.4%	3.4%

EBITDA adj. per quarter



EBIT adj. per quarter



¹⁾ Figures for 2016 without profit contribution from SSC and adj. for JV transaction.

²⁾ Q1 2017 adj. for positive one-off effects from JV transaction of € 85m. Figures for Q2, Q3 and Q4 2017 restructuring expenses/closure in France (€ 11m) and valuation adjustment in IT (€ 4m EBITDA), expenses resulting from tax audit in Austria (€ 5m, mainly for refund of energy supply charge).

³⁾ Q2 2018 adjusted for negative one-off effects from closure of Sempertrans site in China (€ 4m for EBITDA).

⁴⁾ Q3 2019 adjusted for negative one-off effect of € 47m from impairment of Sempermed (adj. for EBIT) and € 4m (EBITDA, EBIT) due to release of provision in Sempermed for Brazilian court case for tax liabilities.

⁵⁾ Q4 2019: impairment figure of Q3 2019 stepped up by € 2m due to additions to assets and FY deviations



Semperflex and Sempertrans (adj. where applicable)

Semperflex (Hoses)

in EUR m	FY 2016 ¹⁾	Q1 2017 adj. ²⁾	Q2 2017 adj. ²⁾	Q3 2017 adj. ²⁾	Q4 2017 adj. ²⁾	FY 2017 adj. ²⁾	Q1 2018	Q2 2018	Q3 2018 adj. ³⁾	Q4 2018	FY 2018	Q1 2019	Q2 2019	Q3 2019	Q4 2019	FY 2019
Revenue	184.9	53.5	53.2	46.8	52.5	206.1	58.8	62.8	53.4	55.1	230.0	61.1	59.7	53.8	48.0	222.7
EBITDA	43.4	11.7	10.5	8.7	10.5	41.4	13.7	14.9	9.3	10.9	48.9	13.9	14.5	10.8	8.7	47.9
EBITDA margin	23.5%	21.8%	19.8%	18.6%	19.9%	20.1%	23.4%	23.8%	17.4%	19.8%	21.3%	22.8%	24.3%	20.1%	18.1%	21.5%
EBIT	35.3	9.6	8.6	6.8	7.8	32.7	11.1	12.3	6.9	8.1	38.4	11.1	11.5	7.7	5.7	36.0
EBIT margin	19.1%	18.0%	16.1%	14.5%	14.8%	15.9%	18.9%	19.7%	12.9%	14.8%	16.7%	18.2%	19.2%	14.3%	11.9%	16.2%

Sempertrans (Conveyor belts)

in EUR m	FY 2016	Q1 2017 adj. ²⁾	Q2 2017 adj. ²⁾	Q3 2017 adj. ²⁾	Q4 2017 adj. ²⁾	FY 2017 adj. ²⁾	Q1 2018	Q2 2018 adj. ³⁾	Q3 2018	Q4 2018	FY 2018	Q1 2019	Q2 2019	Q3 2019	Q4 2019	FY 2019
Revenue	148.4	41.3	36.8	35.7	32.1	146.0	34.6	37.0	37.6	35.5	144.8	30.4	37.8	35.1	30.6	134.0
EBITDA	15.9	0.6	-2.4	-1.4	-2.1	-5.3	0.5	0.8	2.4	0.7	4.4	2.7	5.4	4.6	0.8	13.5
EBITDA margin	10.7%	1.4%	-6.4%	-3.9%	-6.6%	-3.6%	1.4%	2.1%	6.4%	2.1%	3.0%	9.0%	14.2%	13.1%	2.5%	10.1%
EBIT	12.1	-0.3	-3.3	-2.2	-3.0	-8.9	-0.4	-0.1	1.6	-0.4	0.7	1.8	3.8	3.6	-0.3	8.9
EBIT margin	8.2%	-0.8%	-8.9%	-6.3%	-9.6%	-6.1%	-1.1%	-0.2%	4.3%	-1.1%	0.5%	6.0%	10.0%	10.4%	-0.9%	6.7%

¹⁾ Values for 2016 restated, the business unit Sheeting was reclassified from segment Semperflex to segment Semperform.

²⁾ Q1 2017 adj. for positive one-off effects from JV transaction of € 85m. Figures for Q2, Q3 and Q4 2017 restructuring expenses/closure in France (€ 11m) and valuation adjustment in IT (€ 4m EBITDA), expenses resulting from tax audit in Austria (€ 5m, mainly for refund of energy supply charge).

³⁾ Q2 2018 adjusted for negative one-off effects from closure of Sempertrans site in China (€ 4m for EBITDA).



Semperform and Sempermed (adj. where applicable)

Semperform (Window and door profiles, Handrails)

in EUR m	FY 2016 ¹⁾	Q1 2017	Q2 2017	Q3 2017 adj. ⁴⁾	Q4 2017	FY 2017 adj. ⁴⁾	Q1 2018	Q2 2018	Q3 2018	Q4 2018	FY 2018	Q1 2019	Q2 2019	Q3 2019	Q4 2019	FY 2019
Revenue	173.1	45.3	50.1	46.9	42.7	185.0	47.5	50.7	50.3	43.7	192.2	49.9	50.5	47.8	42.4	190.6
EBITDA	30.2	5.0	7.8	5.2	3.6	21.5	4.5	7.3	6.2	3.9	21.9	7.9	8.3	6.6	3.3	26.0
EBITDA margin	17.4%	10.9%	15.5%	11.0%	8.5%	11.6%	9.6%	14.4%	12.2%	8.9%	11.4%	15.7%	16.4%	13.8%	7.8%	13.6%
EBIT	22.5	3.0	5.8	3.2	1.3	13.3	2.4	5.1	4.2	1.5	13.2	5.4	5.9	4.2	0.5	16.0
EBIT margin	13.0%	6.6%	11.5%	6.8%	3.0%	7.2%	5.0%	10.1%	8.4%	3.4%	6.9%	10.9%	11.6%	8.7%	1.1%	8.4%

Sempermed (Gloves)

in EUR m	FY 2016 adj. ²⁾	Q1 2017 adj. ³⁾	Q2 2017 adj. ³⁾	Q3 2017 adj. ⁴⁾	Q4 2017	FY 2017 adj. ^{3) 4)}	Q1 2018	Q2 2018	Q3 2018	Q4 2018	FY 2018	Q1 2019	Q2 2019	Q3 2019 adj. ⁵⁾	Q4 2019	FY 2019
Revenue	346.0	89.2	92.2	78.8	76.9	337.1	80.0	77.1	80.4	73.9	311.5	71.5	76.4	78.2	67.3	293.3
EBITDA	3.4	0.0	1.7	1.6	-1.5	1.8	1.4	-1.3	-0.9	-3.1	-3.9	-0.9	0.6	1.8	-0.1	1.4
EBITDA margin	1.0%	±0.0%	1.9%	2.0%	-2.0%	0.5%	1.8%	-1.7%	-1.1%	-4.2%	-1.3%	-1.2%	0.8%	2.3%	-0.1%	0.5%
EBIT	-10.1	-2.8	-1.2	-1.5	-6.7	-12.1	-2.2	-5.1	-3.9	-3.1	-14.3	-2.8	-1.4	-0.3	-0.9	-5.5
EBIT margin	-2.9%	-3.1%	-1.3%	-1.8%	-8.6%	-3.6%	-2.8%	-6.6%	-4.8%	-4.2%	-4.6%	-3.9%	-1.9%	-0.4%	-1.4%	-1.9%

¹⁾ Values for 2016 restated, the business unit Sheeting was reclassified from segment Semperflex to segment Semperform

²⁾ Adj. for negative one-off effects in Q4 2016 and without profit contribution from SSC for FY 2016

³⁾ Q1 2017 Sempermed adj. for positive one-off effects from JV transaction of € 78m for EBITDA.

⁴⁾ Adj. for expenses resulting from tax audit in Austria, mainly for refund of energy supply charge (€ 2m for Semperform, € 2m for Sempermed)

⁵⁾ Q3 2019 adjusted for negative one-off effect of € 46.8m from impairment of Sempermed (adj. for EBIT) and € 4m (EBITDA, EBIT) due to release of provision in Sempermed for Brazilian court case for tax liabilities.

⁶⁾ Q4 2019: impairment figure of Q3 2019 stepped up by € 2m due to additions to assets and FY deviations



Key figures 2008-2018

Key performance figures											
in EUR m	2009	2010 ¹⁾	2011 ¹⁾	2012	2013	2014 ³⁾	2015 ³⁾	2016 adj. ⁴⁾	2017 adj. ⁵⁾	2018 adj. ⁶⁾	2019 adj. ⁷⁾
Revenue	588.1	689.4	820.0	828.6	906.3	858.3	914.7	852.4	874.2	878.5	840.6
EBITDA	102.8	112.3	110.0	108.7	132.5	101.9	96.2	74.7	35.8	50.3	63.8
EBITDA margin	17.5%	16.3%	13.4%	13.1%	14.6%	11.9%	10.5%	8.8%	4.1%	5.7%	7.6%
EBIT	69.6	82.3	80.4	72.5	87.8	63.8	66.7	41.1	-0.8	15.4	28.2
EBIT margin	11.8%	11.9%	9.8%	8.8%	9.7%	7.4%	7.3%	4.8%	-0.1%	1.7%	3.4%
Earnings after tax	38.8	45.4	51.8	46.2	54.9	37.8	46.4	15.2	-43.9	-17.3	-0.2
EPS²⁾, in EUR	1.89	2.21	2.52	2.25	2.65	1.85	2.26	0.74	-2.13	-1.07	-0.33
Gross cash flow	92.6	91.0	89.4	85.6	116.2	89.9	55.7	48.1	32.2	37.4	46.7
Return on equity	12.5%	12.9%	13.6%	11.4%	13.3%	8.6%	12.8%	4.6%	-15.8%	-4.2%	-16.3%

Balance sheet key figures											
in EUR m	2009	2010 ¹⁾	2011 ¹⁾	2012	2013	2014 ³⁾	2015 ³⁾	2016	2017	2018	2019
Balance sheet total	531.5	593.5	616.7	824.5	852.1	826.3	937.8	1034.5	853.2	768.8	701.8
Equity²⁾	310.6	351.1	379.4	406.2	411.5	443.8	363.3	329.3	278.5	329.5	273.4
Equity ratio	58.4%	59.2%	61.5%	49.3%	48.3%	53.7%	38.7%	31.8%	32.6%	42.9%	39.0%
Investments in tangible and intangible assets	22.7	52.5	45.1	41.2	49.7	67.4	71.8	65.1	74.5	80.8	31.4
Employees, at balance sheet date, FTEs	6,649	7,019	8,025	9,577	10,276	6,888	7,053	6,974	6,838	6,773	6,902

¹⁾ 2011 restated (see Annual Report 2012, Notes 2.18), 2010 not restated.

²⁾ Attributable to shareholders of Semperit AG Holding from ordinary shares, excluding interest from hybrid capital.

³⁾ 2014 and 2015 restated.

⁴⁾ 2016 without profit contribution from SSC / Thai glove JV, impairment Sempermed and trade tax / levies in Brazil.

⁵⁾ 2017 adjusted for positive one-off effects from JV transaction of € 85m (€ 65m for net profit) and negative one-off effects from impairment at Sempermed (€ 26m adj. EBIT, EAT only), from restructuring expenses in France (€ 11m), valuation adjustment in IT (€ 4m EBITDA, € 3m EBIT) and expenses resulting from tax audit in Austria (€ 5m, mainly for refund of energy supply charge).


⁶⁾ 2018 adjusted for negative one-off effects from closure of Sempertrans site in China (€ 4m for EBITDA, € 8m for EBIT and EAT) and for impairment of Sempermed of € 55m (adj. for EBIT and EAT only).

⁷⁾ FY 2019 adjusted for positive one-off effects of € 4m (EBITDA, EBIT, EAT) due to release of provision in Sempermed for Brazilian court case for tax liabilities and for negative one-off effects of € 48.8m from impairment at Sempermed from impairment of Sempermed (adj. for EBIT and EAT)



Overview price indices Butadiene

Price movements for raw materials¹⁾ became highly unpredictable




¹⁾ Selected raw materials are shown for illustration purposes only. Indices based on 01/01/2019 = 100.0




Overview price indices LFO-F-NWE / wire rod

Significant increase for raw material¹⁾ used in industrial segments

Price index LFO-F-NWE



Price index wire rod



¹⁾ Selected raw materials are shown for illustration purposes only. Indices based on 01/01/2019 = 100.0



Product / market position / segment overview, FY 2019

Semperit Group

Group	Industrial Sector			Medical Sector	
	Semperflex	Sempertrans	Semperform ⁴⁾	Sempermed	
Revenue	€ 841m	€ 223m / 26% ¹⁾	€ 134m / 16% ¹⁾	€ 191m / 23% ¹⁾	€ 293m / 35% ¹⁾
EBITDA adj.	€ 64m ²⁾	€ 48m	€ 14m	€ 26m	€ 1m
Employees	6,902 ²⁾	1,672 / 27% ³⁾	939 / 13% ³⁾	990 / 15% ³⁾	3,165 / 44% ³⁾

Products and market position

Hydraulic hoses

3 position globally / leader in hose only



Industrial hoses

2 - 3 position in Europe



Conveyor belts

One of the leading providers for heavyduty steel and textile cord belts



Profiles / Handrails

Leading position in construction (**profiles, piping, gaskets**) and infrastructure (**handrails, sheave liners, rail track**) business with European focus



Examination gloves

Among the top 10 glovemakers in the world



Surgical gloves

Leading position in Europe



¹⁾ Revenue in % of Group revenue.

²⁾ Group figure includes corporate center of € -25m, 136 employees.

³⁾ Employees in % of Group employees.


⁴⁾ The business units Profiles and Rubber

Sheeting were separated from the Semperform segment and are operated as a segment of their own under the name Semperseal as of 1 January 2020.



Shareholder Structure

Shareholder structure



- Semperit is listed on the Vienna Stock Exchange since 1890
- Total of 20,573,434 shares
- B & C Holding Österreich GmbH is part of B & C Privatstiftung, an Austrian based private foundation / trust
- Primary focus of B & C is pursuing the foundation's mission to "foster Austrian entrepreneurship"
- Semperit benefits from a supportive ownership structure with long-term commitment from B & C